“importantly for target specificity, mage-type antigens are not present on the surface of normal tissues, which reduces the risk of side-effects caused by the immune system attacking healthy cells.”
the therapy has shown enough promise to be cleared for a clinical trial involving 80 patients with non-small cell lung cancer later this year.
“this new vaccine platform has the potential to revolutionize cancer treatment,” said adrian hill, lakshmi mittal and family professorship of vaccinology and director of the jenner institute at the university of oxford. “the forthcoming trial in non-small cell lung cancer follows a phase 2a trial of a similar cancer vaccine in
prostate cancer undertaken by the university of oxford that is showing promising results.
“our cancer vaccines elicit strong cd8+ t cell responses that infiltrate tumours and show great potential in enhancing the efficacy of immune checkpoint blockade therapy and improving outcomes for patients with cancer.”
the university has provided an ideal environment for the amalgamation of cutting edge research at a time when the world is still reeling from the spread of covid-19, a virus that has only diminished the ability to detect and treat cancer among the general population in a timely manner. “by bringing these teams together we can continue to address the significant challenge of broadening the positive impact of immunotherapy to benefit more patients,” said tim elliott, kidani professor of immuno-oncology at the university of oxford and co-director of oxford cancer.